Examining a Stabilization Center for Patients with Alcohol or Opioid Intoxication Transported by Paramedics: A Cohort Study of an Emergency Department Diversion Model
Abstract
Abstract Objectives Emergency departments (EDs) face growing strain from increased health-seeking behavior. To preserve finite ED resources, a non-medical stabilization center (SC) was implemented in Toronto, Canada as an alternative destination to receive paramedic-transported patients with suspected acute alcohol or opioid intoxication who would otherwise have been taken to an ED. These patients typically require observation and recovery rather than emergency medical intervention. We described the diversion care model, clinical guideline, patient cohort, and its safety. Methods We conducted a retrospective study of paramedic-transported patients to a SC in Toronto, Canada between December 8, 2022, and December 31, 2024. Eligible patients originated from 9-1-1 calls and were transported either directly (from the community to SC) or indirectly (from the community to an ED, then to SC). Descriptive statistics summarized the patient cohort stratified by transport method, and those later transferred from the SC to an ED. Results A total of 3,744 patients were transported to the SC, of which 3,066 (80.3%) were transported directly, and 738 (19.7%) indirectly. Most patients were male and between the ages of 16 and 49 years. Paramedics performed no medical interventions for 3,557 patients (95.0%), with naloxone administered to only 60 cases (1.6%). A small subgroup of patients were frequent users of the SC, with 3.7% of all patients accounting for 24.6% of all visits. A total of…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 3,744 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.